Parts of your body that you probably don’t wash well

, , , ,

If want you your body to be squeaky clean, you have to do a whole lot better than rubbing soap on your body.

These are the parts that you should be lathering up regularly to keep them clean, fresh, and free of potentially harmful bacteria.

1. Behind Your Ear

The warm and recessed area of your ears is full of sebaceous glands which secrete sebum that provides an ideal hiding place for Staph aureus and Tinea capitis. If not cleaned daily, may start to produce a musty odour

2. Belly Button

Belly buttons are warm, with nooks and crevices, which make them a great place for bacteria to hide. Swab your belly button daily with a cotton swab soaked in warm, soapy water or alcohol.

If you have a pierced belly button, it’s even more important to wash it regularly to prevent infections.

3. Tongue

A lot of the time, people only think of their teeth and gums when talking about dental hygiene and do not provide enough attention to the tongue, or they think that by using mouthwash, they can get it clean enough.

However, the tongue has lots of little ridges and bumps that can hide bacteria, resulting in bad breath and even tooth damage if not cleaned regularly.

Brush your tongue with your toothbrush while you are brushing your teeth or use a tongue scraper.

4. Scalp

While you may wash your hair regularly, how much attention are you paying to your scalp? While it’s not necessary to wash your hair daily, it is important to scrub and massage your scalp daily to avoid buildup of dead skin cells, that body mites and bacteria feast on.

Massaging your scalp daily with warm water not only increases blood flow but helps to manually remove the dead cells which can lead to dandruff

5. Your Back

Although your back gets wet while you’re standing in the shower, it needs to get much mor attention. You can buy a back scrubber or have your partner wash it for you with an exfoliating bath sponge, loofah, or washcloth at least two to three times a week to reduce the risk of developing skin and soft-tissue infections.

6. Under Your Fingernails

While you most likely wash your hands after using the restroom, but if you’re not scrubbing under your nails, you’re only doing half the job.

Faecal bacteria can set up shop and colonize in the area under your nails, and it is best to soak a cotton swab with warm, soapy water and swabbing it under your nails to gently remove dirt and debris. Keeping nails short can also help prevent bacteria from thriving.

‘Flesh-eating’ STD appears in England

, , ,

A rare sexually transmitted disease that causes flesh-eating ulcers on patients’ genitalia has popped up in England, the Lancashire Post reported.

An unnamed female patient, who lives in Southport, and is between the ages of 15 and 25, reportedly was diagnosed with donovanosis within the last 12 months.

Donovanosis, which is spread through sexual intercourse with an infected patient, or by coming into contact with a patient’s infected ulcer, is typically seen in India, New Guinea, parts of the Caribbean, central Australia and southern Africa.

According to the Center for Diseases Control and Prevention (CDC), the painless disease causes progressive ulcerative lesions on the genitals or perineum, which are prone to heavy bleeding.

Patients are at risk of extragenital infections that can occur in the pelvic regions, or in intra-abdominal organs, bones or mouth. The lesions may also develop secondary bacterial infections.

While antibiotic treatment may stop the progression of lesions, patients are at risk of relapse for 6-18 months post-treatment. According to the British Association for Sexual Health and HIV (BASHH), there have been no prior cases reported in the U.K.

The woman’s case came to light through a Freedom of Information request submitted by, the Lancashire Post reported.

A pharmacist with told the news outlet that any delay in treatment “could cause the flesh around the genitals to literally rot away.”

An update on the infected patient was not provided, nor was it clear if any sexual partners she had encountered were also infected. Coming into contact with a victim’s bleeding ulcer could be enough to transmit the disease.

The website submitted the request as part of its “The Great British STI Taboo” investigation, which reported that 69 percent of the 1,000 British adults polled had never been tested for an STD.

The investigation also reported that in 2017, 420,000 STDs were diagnosed in England, with chlamydia accounting for 48 percent of cases.

All You Need To Know About the Ojude-Oba Festival

, , , ,

The Muslim annual Eid-el Kabir celebration in Ijebu land, Ogun State, South-West Nigeria, comes with the colorful and spectacular “Ojude-Oba” festival.

The festival sees the gathering of natives of Ijebu land at the palace of the Awujale, the paramount ruler of the land.

Origin of the Ojude-Oba festival

Long before the Ojude-Oba festival became an all-encompassing gig, it was a small gathering of adherents and followers of the Islamic religion.

The festival was first observed over 100 years ago, at the time the first Muslim converts in Ijebu-ode paid homage to the Awujale of Ijebuland to express their gratitudes over the freedom he gave them to practice their religion.

Today, however, the festival has transcended religious lines and now attracts people of all creeds as well as tourists from within and outside Nigeria.

Venue of the Festival

The festival is held in Ijebu-Ode town.

When the Ojude-Oba Festival is held

The festival is celebrated on the 3rd day of Eid al-Adha.

Major activities of the event

  • Parade by different age grades (Regberegbes)

Three different age-grades display their colourful attires

Male Regberegbes on parade during the Ojude-Oba festival in Ijebu land

Male Regberegbes on parade

Both genders have different categories of ‘regberegbes’. Both genders belonging to different age-grades will jostle to outshine each other. The winners are awarded cash prizes

Female Regberegbes on parade during the Ojude-Oba festival

Female Regberegbes on parade

  • Horse-riding

There are different horse riding families. Each led by a ‘Balogun’. Balogun is the descendants of Ijebu war heroes.

Some of the horse-riding families include:

Balogun Odunuga, Balogun Bello Odueyungbo Kuku, Balogun Agboola Alausa, Balogun Alatishe, Balogun Otubu, Balogun Adesoye, Balogun Odejayi, Balogun Adesoye Onasanya, Balogun Towobola, Balogun Aregbesola and Balogun Ajibike Odedina.

Their entry is announced by intermittent gunshots which send almost everyone into a frenzy

The Baloguns

Scientist record breakthrough in HIV, malaria vaccine



Findings have shown that an experimental HIV-1 vaccine regimen is well-tolerated and generated comparable and robust immune responses against (Human Immunodeficiency Virus) HIV in healthy adults and rhesus monkeys.

Also, another separate research has shown that higher levels of Plasmodium falciparum antibodies are protective against severe malaria in children living in Papua New Guinea.

Children who have higher levels of antibodies to a specific short amino acid sequence in the malaria parasite, P. falciparum, have much lower rates of clinical and severe malaria.

This amino acid sequence, an antigen, is similar among P. falciparum strains elsewhere in the world, suggesting that this antigen would make a good target for a malaria vaccine.

The research is published in Infection and Immunity, a journal of the American Society for Microbiology.

As published in The Lancet, based on the results from the clinical trial that involved nearly 400 healthy adults, a phase 2b trial has been initiated in Southern Africa to determine the safety and efficacy of the HIV-1 vaccine candidate in 2,600 women at risk for acquiring HIV.

This is one of only five experimental HIV-1 vaccine concepts that have progressed to efficacy trials in humans in the 35 years of the global HIV/AIDS epidemic.
Previous HIV-1 vaccine candidates have typically been limited to specific regions of the world.

The experimental regimens tested in this study are based on ‘mosaic’ vaccines that take pieces of different HIV viruses and combine them to elicit immune responses against a wide variety of HIV strains.

Led Researcher, Professor of Medicine, Harvard Medical School, Boston, and Director of the Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Centre, Dan Barouch said: “These results represent an important milestone.

This study demonstrates that the mosaic Ad26 prime, Ad26 plus gp140 boost HIV vaccine candidate induced robust immune responses in humans and monkeys with comparable magnitude, kinetics, phenotype, and durability and also provided 67per cent protection against viral challenge in monkeys.”
He added: “These results should be interpreted cautiously.

The challenges in the development of an HIV vaccine are unprecedented, and the ability to induce HIV-specific immune responses does not necessarily indicate that a vaccine will protect humans from HIV infection.

We eagerly await the results of the phase 2b efficacy trial called HVTN705, or ‘Imbokodo’, which will determine whether or not this vaccine will protect humans against acquiring HIV.”

Almost 37 million people worldwide are living with HIV/AIDS, with an estimated 1.8 million new cases every year. A safe and effective preventative vaccine is urgently needed to curb the HIV pandemic.

In the 35 years of the HIV epidemic, only four HIV vaccine concepts have been tested in humans, and only one has provided evidence of protection in an efficacy trial — a canarypox vector prime, gp120 boost vaccine regimen tested in the RV144 trial in Thailand lowered the rate of human infection by 31% but the effect was considered too low to advance the vaccine to common use.

A key hurdle to HIV vaccine development has been the lack of direct comparability between clinical trials and preclinical studies.

To address these methodological issues, Barouch and colleagues evaluated the leading mosaic adenovirus serotype 26 (Ad26)-based HIV-1 vaccine candidates in parallel clinical and pre-clinical studies to identify the optimal HIV vaccine regimen to advance into clinical efficacy trials.

The APPROACH trial recruited 393 healthy, HIV-uninfected adults (aged 18-50 years) from 12 clinics in east Africa, South Africa, Thailand, and the USA between February 2015 and October 2015.

Volunteers were randomly assigned to receive either one of seven vaccine combinations or a placebo, and were given four vaccinations over the course of 48 weeks.

To stimulate, or ‘prime’, an initial immune response, each volunteer received an intramuscular injection of Ad26.Mos.HIV at the start of the study and again 12 weeks later.

The vaccine containing ‘mosaic’ HIV Env/Gag/Pol antigens was created from many HIV strains, delivered using a nonreplicating common-cold virus (Ad26).
To ‘boost’ the level of the body’s immune response, volunteers were given two additional vaccinations at week 24 and 48 using various combinations of Ad26.Mos.HIV or a different vaccine component called Modified Vaccinia Ankara (MVA) with or without two different doses of clade C HIV gp140 envelope protein containing an aluminium adjuvant.

Results showed that all vaccine regimens tested were capable of generating anti-HIV immune responses in healthy individuals and were well tolerated, with similar numbers of local and systemic reactions reported in all groups, most of which were mild-to-moderate in severity.
Five participants reported at least one vaccine-related grade 3 adverse events such as abdominal pain and diarrhea, postural dizziness, and back pain.
No grade 4 adverse events or deaths were reported.

In a parallel study, the researchers assessed the immunogenicity and protective efficacy of the same Ad26-based mosaic vaccine regimens in 72 rhesus monkeys using a series repeated challenges with simian-human immunodeficiency virus (SHIV) — a virus similar to HIV that infects monkeys.